Skip to main content
. 2022 Dec 15;10(12):e005538. doi: 10.1136/jitc-2022-005538

Table 1.

Focality of papillary thyroid cancer in NOD.H2h4 TPO-CRE-ER BRAFv600E mice treated with immune checkpoint inhibitors (ICIs), according to the status of iodine-exacerbated thyroiditis (IET)

No of mice Papillary thyroid cancer foci P value
None One ≥2
Concomitant IET: 0.107
 Control 18 0 5 13
 LAG-3 Ab 8 3 2 3
 PD-1 Ab 8 4 1 3
 TIM-3 Ab 6 2 1 3
No IET: 0.974
 Control 19 3 4 12
 LAG-3 Ab 6 1 1 4
 PD-1 Ab 7 2 1 4
 TIM-3 Ab 6 2 1 3
Pre-existing IET: 0.242
 Control 21 10 9 2
 LAG-3 Ab 9 4 3 2
 PD-1 Ab 7 2 1 4
 TIM-3 Ab 7 2 2 3
    
    
No of mice Papillary thyroid cancer Foci P value
None One ≥2
Concomitant IET: 0.008
 Control 18 0 5 13
 ICI 22 9 4 9
 No IET: 0.70
 Control 19 3 4 12
 ICI 19 5 3 11
Pre-existing IET: 0.07
 Control 21 10 9 2
 ICI 23 8 6 9

The data are reported both separating by specific ICIs (top) and condensing all ICI-treated animals within the same group (bottom). The P column reports the p value for the χ2 test.

LAG-3, lymphocyte activation gene 3; PD-1, programmed death-1; TIM-3, T-cell immunoglobulin and mucin domain 3.